PFE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pfizer Inc (PFE) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While there are some positive long-term catalysts such as the extension of Vyndamax exclusivity and recent approvals of Hympavzi and VEPPANU, the short-term challenges, including leadership transition and weak price momentum, make it prudent to hold off for now. The stock lacks strong trading signals and has mixed sentiment from analysts and options data, suggesting limited immediate upside.
The MACD is slightly positive but contracting, indicating weak momentum. RSI is at 28.356, which is neutral and does not signal overbought or oversold conditions. The stock is trading near its support level of 25.168, with resistance at 26.352. Converging moving averages suggest indecision in the market.
Extension of Vyndamax exclusivity to
Recent approvals of Hympavzi and VEPPANU, strengthening the long-term pipeline.
Congress trading data shows a recent purchase, indicating positive sentiment from influential figures.
CFO Dave Denton's resignation has raised concerns about leadership continuity.
Stock price dropped 2.74% in regular trading, reflecting weak investor confidence.
Analysts maintain mostly Neutral or Equal Weight ratings, with modest price target increases.
No detailed financial data available for the latest quarter. However, Pfizer reaffirmed its fiscal 2026 guidance, projecting revenues between $59.5 billion and $62.5 billion.
Analysts have mixed views, with most maintaining Neutral or Equal Weight ratings. Price targets range from $26 to $36, with recent adjustments reflecting cautious optimism but no strong conviction for significant upside in the near term.
